{"result": "{\n    \"title\": \"TRIAL and Supplementary Appendix\",\n    \"summary\": \"The community is centered around the TRIAL, a comprehensive clinical study focused on critical care, and its associated Supplementary Appendix. The TRIAL involves multiple research components, including comparisons of treatment methods for Acute Respiratory Distress Syndrome (ARDS) and shock, and is supported by detailed data and analyses in the Supplementary Appendix. Key entities include the Ethics Committee, SAS Software, and various patient groups, all contributing to the study's execution and findings.\",\n    \"rating\": 8.5,\n    \"rating_explanation\": \"The impact severity rating is high due to the TRIAL's potential to significantly influence critical care practices and patient outcomes.\",\n    \"findings\": [\n        {\n            \"summary\": \"Comprehensive scope of the TRIAL\",\n            \"explanation\": \"The TRIAL is a multifaceted clinical study that addresses several critical care research objectives. It includes comparisons of early continuous neuromuscular blockade with usual care in ARDS patients, the effects of hydrocortisone versus placebo, and different blood transfusion thresholds. Additionally, it evaluates High-Frequency Oscillatory Ventilation (HFOV) against standard methods and the impact of various vasopressor agents on shock patients. This broad scope aims to enhance understanding and improve treatment strategies in critical care settings [Data: Entities (121); Relationships (176, 313, 285, 110, 501, +more)].\"\n        },\n        {\n            \"summary\": \"Role of the Supplementary Appendix\",\n            \"explanation\": \"The Supplementary Appendix is a crucial document that provides additional information and data related to the TRIAL. It includes supplementary figures, tables, and detailed statistical analyses, offering further insights into the study's findings. This document serves as an essential resource for understanding the detailed data and analyses that support the study's conclusions, thereby enhancing the transparency and reliability of the TRIAL's outcomes [Data: Entities (99); Relationships (430, 278, 434, 432, 429, +more)].\"\n        },\n        {\n            \"summary\": \"Ethics and regulatory oversight\",\n            \"explanation\": \"The Ethics Committee played a vital role in the TRIAL by approving the study at each participating center and ensuring adherence to ethical standards. This oversight is crucial for maintaining the integrity and ethical conduct of the research, which involves vulnerable patient populations in critical care settings. The committee's involvement underscores the importance of ethical considerations in clinical research [Data: Entities (327); Relationships (490, 818)].\"\n        },\n        {\n            \"summary\": \"Statistical analysis using SAS Software\",\n            \"explanation\": \"SAS Software, version 9.3, was employed for all statistical analyses in the TRIAL, highlighting its pivotal role in facilitating rigorous data examination and interpretation. The use of advanced analytics software ensures that the study's findings are based on robust statistical methods, thereby enhancing the credibility and reliability of the results [Data: Entities (119); Relationships (481, 482, 39)].\"\n        },\n        {\n            \"summary\": \"Patient recruitment and study timeline\",\n            \"explanation\": \"The TRIAL had a structured timeline, beginning patient recruitment on September 2, 2008, and completing it on June 23, 2015. The study faced suspensions, notably on October 25, 2011, due to the withdrawal of Xigris, and resumed on May 12, 2012, and October 7, 2014, after subsequent suspensions. The trial was completed on December 23, 2015. This timeline reflects the challenges and regulatory processes involved in conducting large-scale clinical trials [Data: Entities (654, 651, 648, 650, 647); Relationships (512, 509, 506, 508, 507, +more)].\"\n        }\n    ]\n}", "input": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\n121,TRIAL,\"The TRIAL is a comprehensive clinical study encompassing multiple research objectives related to critical care. It includes a comparison of early continuous neuromuscular blockade with usual care in patients suffering from moderate-to-severe Acute Respiratory Distress Syndrome (ARDS). Additionally, the study investigates the effects of hydrocortisone versus a placebo, focusing on critical outcomes such as mortality and the time required for the resolution of shock. Another aspect of the TRIAL involves comparing patient outcomes based on different blood transfusion thresholds. Furthermore, the study evaluates the effectiveness of High-Frequency Oscillatory Ventilation (HFOV) compared to standard ventilation methods. Lastly, the TRIAL examines the impact of various vasopressor agents on patients experiencing shock. Through these diverse research components, the TRIAL aims to enhance understanding and improve treatment strategies in critical care settings.\",40\n99,SUPPLEMENTARY APPENDIX,\"The \"\"SUPPLEMENTARY APPENDIX\"\" is a comprehensive document that provides additional information and data related to the study and trial. It includes supplementary figures and tables referenced in the main text, as well as detailed statistical analyses and post hoc analyses. The appendix offers further insights into the study's findings by presenting additional methods, patient data, and reasons for patient exclusion. It also contains definitions of ischemic events and a list of board members and guidelines for the study. This document serves as an essential resource for understanding the detailed data and analyses that support the study's conclusions.\",16\n119,SAS SOFTWARE,\"SAS Software is a comprehensive software suite utilized for advanced analytics, business intelligence, data management, and predictive analytics. It is widely recognized as a statistical analysis system, particularly in the context of data analysis for studies. In the specific study referenced, SAS Software, version 9.3, was employed for all statistical analyses, underscoring its pivotal role in facilitating rigorous data examination and interpretation.\",3\n327,ETHICS COMMITTEE,The ETHICS COMMITTEE approved the trial at each participating center and also approved the protocol for the CORTICUS study at each participating ICU.,2\n329,28 DAYS,The maximum duration of the study period for the trial,1\n230,ACUTE PHYSIOLOGY AND CHRONIC HEALTH EVALUATION (APACHE) II,A scoring system used to assess the severity of disease in patients,1\n654,\"DECEMBER 23, 2015\",The date when the trial was completed,1\n330,EPINEPHRINE,Epinephrine is a vasopressor agent used as rescue therapy in the trial,1\n560,FIGURE 1,A figure in the study illustrating the rate of survival and the risk of death at 90 days according to subgroup,1\n561,FIGURE 2,A figure in the study showing the cumulative incidence function of time from randomization to resolution of shock,1\n333,HEMODYNAMIC STABILITY,\"Hemodynamic stability refers to the achievement of a mean arterial pressure of 65 mm Hg, a key goal in the trial\",1\n651,\"JULY 22, 2014\",The date when the trial was suspended for the second time at the request of the data and safety monitoring board,1\n648,\"JUNE 23, 2015\",The date when the last patient was recruited for the trial,1\n650,\"MAY 12, 2012\",The date when the trial resumed after the first suspension,1\n559,MEDICAL-SURGICAL ICUS,\"Intensive care units where the trial was conducted, located in various countries including Australia, the United Kingdom, New Zealand, Saudi Arabia, and Denmark\",1\n653,\"OCTOBER 1, 2014\",The date when the data and safety monitoring board confirmed the trial's conformity to the marketing-authorization application,1\n649,\"OCTOBER 25, 2011\",The date when the trial was first suspended due to the withdrawal of Xigris,1\n652,\"OCTOBER 7, 2014\",The date when the trial resumed after the second suspension,1\n647,\"SEPTEMBER 2, 2008\",The date when the first patient was recruited for the trial,1\n120,SPSS SOFTWARE,SPSS Software is a software package used for statistical analysis,1\n328,WRITTEN INFORMED CONSENT,Consent obtained from patients or next of kin before participating in the trial,1\n332,VASOPRESSOR AGENT,Vasopressor agents are medications used to treat shock by increasing blood pressure,1\n315,TABLE S8,A specific table in the Supplementary Appendix that reports findings related to the trial,1\n316,TABLE S9,A specific table in the Supplementary Appendix that presents a breakdown of specific adverse events,1\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\n176,SEPTIC SHOCK,TRIAL,The trial focused on patients with severe septic shock,110\n313,ICU,TRIAL,\"The trial, referred to as \"\"TRIAL,\"\" was conducted in the Intensive Care Units (ICU) where patients were treated. It involved monitoring patients in the ICU to gather relevant data and insights.\",86\n285,PLACEBO GROUP,TRIAL,The placebo group was a part of the trial,75\n110,PLACEBO,TRIAL,The trial involved administering a placebo to one group of patients,71\n434,SUPPLEMENTARY APPENDIX,EGDT,The Supplementary Appendix contains additional figures and tables related to the study involving EGDT,67\n501,TRIAL,HYDROCORTISONE GROUP,The hydrocortisone group was a part of the trial,62\n201,HYDROCORTISONE,TRIAL,The trial involved administering hydrocortisone to one group of patients,61\n430,SUPPLEMENTARY APPENDIX,TRIAL,\"The Supplementary Appendix contains additional data, figures, and analysis related to the trial, providing further information to support the findings and conclusions of the study.\",56\n482,SAS SOFTWARE,EGDT,SAS software was used to perform statistical analyses for the study involving EGDT,54\n486,TRIAL,CONTROL GROUP,The control group was part of the trial studying ARDS treatment,54\n504,TRIAL,DATA AND SAFETY MONITORING BOARD,The Data and Safety Monitoring Board monitored the trial's safety and data integrity,54\n496,TRIAL,VASOPRESSIN,Vasopressin was used as rescue therapy in the trial,53\n278,PLACEBO GROUP,SUPPLEMENTARY APPENDIX,The Supplementary Appendix contains additional data and figures related to the placebo group,51\n257,SAS INSTITUTE,TRIAL,SAS Institute provided the statistical software used for the trial's analysis,51\n494,TRIAL,NOREPINEPHRINE,Norepinephrine was one of the vasopressor agents tested in the trial,50\n265,HOSPITAL,TRIAL,The trial was conducted in a hospital setting where patients were treated,49\n487,TRIAL,INTERVENTION GROUP,The intervention group was part of the trial studying ARDS treatment,48\n60,STEERING COMMITTEE,TRIAL,The steering committee decided to terminate the trial,48\n493,TRIAL,DOPAMINE,Dopamine was one of the vasopressor agents tested in the trial,47\n499,TRIAL,ADVERSE EVENTS,Adverse events were monitored and categorized during the trial,45\n484,TRIAL,LOWER-THRESHOLD GROUP,The lower-threshold group was one of the two groups compared in the trial,44\n485,TRIAL,HIGHER-THRESHOLD GROUP,The higher-threshold group was one of the two groups compared in the trial,44\n481,SAS SOFTWARE,TRIAL,SAS Software was utilized to conduct statistical analyses in the trial.,43\n490,TRIAL,ETHICS COMMITTEE,The ethics committee approved the trial at each participating center,42\n489,TRIAL,O'BRIEN–FLEMING METHOD,The O'Brien–Fleming method was used to determine early stopping criteria in the trial,42\n492,TRIAL,28 DAYS,The trial had a maximum study period of 28 days,41\n488,TRIAL,ACUTE PHYSIOLOGY AND CHRONIC HEALTH EVALUATION (APACHE) II,The APACHE II score was used to assess patient severity in the trial,41\n512,TRIAL,\"DECEMBER 23, 2015\",\"The trial was completed on December 23, 2015\",41\n495,TRIAL,EPINEPHRINE,Epinephrine was used as rescue therapy in the trial,41\n502,TRIAL,FIGURE 1,Figure 1 is part of the trial documentation illustrating survival rates,41\n503,TRIAL,FIGURE 2,Figure 2 is part of the trial documentation showing time to resolution of shock,41\n498,TRIAL,HEMODYNAMIC STABILITY,Achieving hemodynamic stability was a key goal in the trial,41\n509,TRIAL,\"JULY 22, 2014\",\"The trial was suspended on July 22, 2014, at the request of the data and safety monitoring board\",41\n506,TRIAL,\"JUNE 23, 2015\",\"The trial completed patient recruitment on June 23, 2015\",41\n508,TRIAL,\"MAY 12, 2012\",\"The trial resumed on May 12, 2012, after the first suspension\",41\n500,TRIAL,MEDICAL-SURGICAL ICUS,The trial was conducted in medical-surgical ICUs across multiple countries,41\n511,TRIAL,\"OCTOBER 1, 2014\",\"The data and safety monitoring board confirmed the trial's conformity on October 1, 2014\",41\n507,TRIAL,\"OCTOBER 25, 2011\",\"The trial was suspended on October 25, 2011, due to the withdrawal of Xigris\",41\n510,TRIAL,\"OCTOBER 7, 2014\",\"The trial resumed on October 7, 2014, after the second suspension\",41\n505,TRIAL,\"SEPTEMBER 2, 2008\",\"The trial began recruiting patients on September 2, 2008\",41\n483,SPSS SOFTWARE,TRIAL,SPSS Software was used to perform statistical analyses in the trial,41\n491,TRIAL,WRITTEN INFORMED CONSENT,Written informed consent was obtained from patients or next of kin for participation in the trial,41\n497,TRIAL,VASOPRESSOR AGENT,Vasopressor agents were central to the trial's investigation into treating shock,41\n432,SUPPLEMENTARY APPENDIX,CONTROL GROUP,The Supplementary Appendix contains additional data on the control group's physiological responses,30\n429,SUPPLEMENTARY APPENDIX,STUDY GROUP,The Supplementary Appendix contains detailed data and figures related to the study group,25\n431,SUPPLEMENTARY APPENDIX,HFOV GROUP,The Supplementary Appendix contains additional data on the HFOV group's physiological responses,25\n366,NEJM.ORG,SUPPLEMENTARY APPENDIX,The Supplementary Appendix is available with the full text of the article at NEJM.org,24\n427,SUPPLEMENTARY APPENDIX,TRISS TRIAL,The Supplementary Appendix provided additional data and information for the TRISS trial,22\n433,SUPPLEMENTARY APPENDIX,WRITING COMMITTEE,The Supplementary Appendix contains additional methods and figures related to the study overseen by the writing committee,22\n439,SUPPLEMENTARY APPENDIX,EXECUTIVE COMMITTEE,The Supplementary Appendix contains full details of the trial protocol overseen by the Executive Committee,21\n425,CISATRACURIUM GROUP,SUPPLEMENTARY APPENDIX,The Supplementary Appendix contains additional data and figures related to the cisatracurium group,20\n428,SUPPLEMENTARY APPENDIX,MANAGEMENT COMMITTEE,\"The management committee reviewed study results, and additional details are available in the Supplementary Appendix\",19\n437,SUPPLEMENTARY APPENDIX,STATA/SE SOFTWARE,Stata/SE software was used to perform the statistical analyses detailed in the Supplementary Appendix,18\n438,SUPPLEMENTARY APPENDIX,AUTHORS,Authors provide additional information in the Supplementary Appendix,18\n435,SUPPLEMENTARY APPENDIX,TABLE S8,\"Table S8 is part of the Supplementary Appendix, providing additional findings related to the trial\",17\n436,SUPPLEMENTARY APPENDIX,TABLE S9,\"Table S9 is part of the Supplementary Appendix, providing a breakdown of specific adverse events\",17\n818,ETHICS COMMITTEE,CORTICUS STUDY,The ethics committee approved the protocol for the CORTICUS study,14\n39,APACHE II,SAS SOFTWARE,SAS software was used to analyze data including APACHE II scores,14\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "parameters": {"model": "gpt-4o", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 2000, "n": 1}, "history": null}